Behavioral and Neural Characteristics of Adaptive Speech Motor Control
University of Washington · with National Institutes of Health (NIH), National Institute on Deafness and Other Communication Disorders (NIDCD) · NCT06164717
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 4+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 507
- US sites recruiting
- 1
- Study start
- January 1, 2023
- Record last updated
- December 11, 2023
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study meets the NIH definition of a clinical trial, but is not a treatment study. Instead, the goal of this study is to investigate how hearing ourselves speak affects the planning and execution of speech movements. The study investigates this topic in both typical speakers and in patients with Deep Brain Stimulation (DBS) implants. The main questions it aims to answer are:
- Does the way we hear our own speech while talking affect future speech movements?
- Can the speech of DBS patients reveal which brain areas are involved in adjusting speech movements? Participants will read words, sentences, or series of random syllables from a computer monitor while their speech is being recorded. For some participants, an electrode cap is also used to record brain activity during these tasks. And for DBS patients, the tasks will be performed with the stimulator ON and with the stimulator OFF.
Being studied: Auditory feedback perturbation during speech; Visual feedback perturbation during reaching; DBS stimulation ON/OFF
Conditions: Speech
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
General inclusion criteria
- native speaker of American English
- no communication or neurological problems (except for subjects in the DBS group)
- 250-4000 Hz pure tone hearing thresholds equal to or better than 25 dB HL for children and young adults and equal to or better than 35 dB HL for older adults
- no medications that affect sensorimotor functioning (except for in the DBS group)
- adult subjects: 18 years of age or older
- typical children: 4;0 to 6;11 [years;months] or 10;0 to 12;11 [years;months])
Specific inclusion criteria for children
- scoring above the 20th percentile on the Peabody Picture Vocabulary Test (PPVT-5), Expressive Vocabulary Test (EVT-3), Goldman-Fristoe Test of Articulation (GFTA-3), and either Test of Early Language Development (TELD-4) or (for children age 8 or older) Clinical Evaluation of Language Fundamentals (CELF-5).
Specific inclusion criteria for DBS patients:
- bilateral electrodes implanted in either the ventral intermediate nucleus of the thalamus (Vim; a target site for patients with essential tremor) or subthalamic nucleus (STN; a target site for patients with Parkinson's disease)
Recruiting US locations
University of Washington
Seattle, WA 98105
Site contact: Patrick Olsen · 206-685-7792 · kolsen@uw.edu
Study contacts (from the official record)
- Ludo Max · 206-543-2674 · ludomax@uw.edu
Similar studies in Washington
All healthy volunteers studies in Washington →- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Seattle, WA + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults
GlaxoSmithKline
- Location
- Seattle, WA + 2 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
GlaxoSmithKline
- Location
- Seattle, WA + 5 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingHealthy volunteersPhase 1/Phase 2
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
Vega Therapeutics, Inc
- Location
- Seattle, WA + 9 other US sites
- Eligibility basics
- Ages 12–60